KAIROS PHARMA, LTD. FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (the “Agreement”), dated as of [_____], is by and between Kairos Pharma, Ltd., a Delaware corporation (the “Company”) and [_____] (the “Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into as of the ____ day of September, 2023, by and between Kairos Pharma, Ltd., a Delaware corporation (the “Company”), and Neil Bhowmick an individual residing at the address set forth on Schedule A hereto (the “Executive”).
Exclusive License AgreementExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is entered into as of this 2nd day of June 2021 (“Effective Date”) by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, and Enviro Therapeutics, Inc., (“Licensee”), with offices at 2355 Westwood Blvd., #139, Los Angeles, CA 90069.
EXCLUSIVE OPTION AGREEMENTExclusive Option Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
THIS EXCLUSIVE OPTION AGREEMENT (“Agreement”) is entered into this 16th day of March 2020 (“Effective Date”) by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), with offices at 8700 Beverly Boulevard, Los Angeles, CA 90048, and ENVIRO THERAPEUTICS, INC., a C corporation (hereinafter, “Licensee”), with offices at 2355 Westwood Blvd. #139, Los Angeles CA 90064 (each, a “Party,” and together, the “Parties”).
KAIROS PHARMA, LTD. CONVERTIBLE NOTEConvertible Note • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • New York
FOR VALUE RECEIVED, Kairos Pharma, Ltd. a California corporation (“Kairos Pharma” or the “Maker”), hereby promises to pay to the order of _________________________ (the “Subscriber”), or registered assigns (together with the Subscriber, the “Holder”), the amount set out above as the Original Principal Amount, as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise (the “Principal”), when due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest (“Interest”) on any outstanding Principal at the applicable Interest Rate from the date set out above as the Issuance Date (the “Issuance Date”) until the same becomes due and payable, upon the Maturity Date or acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof).
KAIROS PHARMA, LTD. Los Angeles CA 90064Director Offer Letter • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • Delaware
Kairos Pharma, Ltd. (the “Company”) thanks you in advance for providing your service as a member of its board of directors (the “Board”). We believe that your background and experience will be a significant asset to the Company, and we look forward to your participation on the Board. This letter agreement (this “Agreement”) shall constitute an agreement between you and the Company, effective [*], 2023 (the “Effective Date”), and contains all the terms and conditions relating to the services that you agree to provide to the Company.
Re: Exclusive Option Agreement – Amendment (Depletion of mtDNA)Exclusive Option Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Upon execution by you, this letter will serve as the Amendment (“Amendment”) to the Exclusive Option Agreement entered on March 16, 2020 (“Agreement”), by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”), and Enviro Therapeutics, Inc. (“Licensee”) for the above-referenced technology.
License and Supply AgreementLicense and Supply Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • New York
WHEREAS, Tracon is the holder of multiple inactive INDs for the Antibody TRC105 (“Product”) in the United States, such INDs (the “Product INDs”) are listed in Appendix B;
Cedars-Sinai Medical Center Los Angeles, California 90048-1865 Attention: Vice President, Intellectual Property Re: Exclusive License Agreement dated August 30, 2019 – Amendment Dear Cedars-Sinai Medical Center:Exclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Reference is made to that certain Exclusive License Agreement regarding the technology titled “Methods of generating activated T cells for cancer therapy” dated August 30, 2019 (as amended from time to time, the “License Agreement”) by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and ACTCELL BIOPHARMA, INC., a California corporation (“ACTCELL”). Kairos Pharma, Ltd, a California corporation (“Kairos”) is the successor-by-merger to ACTCELL’s rights and obligations under the License Agreement. Kairos shall be referred to hereinafter as the “Licensee.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is entered into as of this 1st day of October 2017 (“Effective Date”) by and between Cedars-Sinai Medical CENTER, a California nonprofit public benefit corporation (“CSMC”), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, on behalf of itself and the Board of Trustees of the Leland Stanford Junior University, a California nonprofit public benefit corporation (“Stanford”, and together with CSMC, “Licensors”), with offices at 3000 El Camino Real, Building 5, Suite 300, Palo Alto, CA 94306, and Kairos Pharma Ltd. f/k/a NanoGB13, INC., a California corporation (“Licensee”), with offices at 565 Esplanade, Suite 206, Redondo Beach, CA 90277.
SUBSCRIPTION AGREEMENTSubscription Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • New York
Subscription. The undersigned (sometimes referred to herein as the “Investor”) hereby subscribes for and agrees to purchase the principal amount of the Notes (as defined below) of Kairos Pharma, Ltd., a California corporation (the “Company” or “Kairos”), for the purchase price (the “Purchase Price”) set forth on the signature page hereto, on the terms and conditions described herein and in Exhibits A, B, C, D, E, F and G hereto (collectively, the “Offering Documents”). Terms not defined herein are as defined in the Offering Documents. The Company is seeking to raise, through a private placement of the Notes pursuant to Rule 506(b) promulgated under the Securities Act of 1933, as amended, up to $3,000,000 principal amount of Notes (the “Maximum Offering Amount”) in this Offering, although the Company and Boustead reserve the right, in their sole discretion, to increase the Maximum Offering Amount of Notes to an aggregate principal amount that is in excess of $3,000,000. The minimum amou
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
This FIRST AMENDMENT TO EXCLUSIVE LICENSEE AGREEMENT (this “First Amendment”) is made and entered into as of April 18, 2022 (“First Amendment Effective Date”) by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and ENVIRO THERAPEUTICS INC., a California corporation (“Licensee”), and as of the First Amendment Effective Date, amends that certain Exclusive License Agreement by and between CSMC and Licensee, dated June 2, 2021 (the “Agreement”).
Re: Exclusive License Agreement dated October 1, 2017 - AmendmentExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Reference is made to that certain Exclusive License Agreement regarding the technology titled “Composition and Methods for Treating Fibrosis” dated October 1, 2017 (as amended from time to time, the “License Agreement”) by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and Kairos Pharma, Ltd, a California corporation (“Licensee”).
Cedars-Sinai Medical Center Los Angeles, California 90048-1865 Attention: Vice President, Intellectual Property Re: Exclusive License Agreement dated October 1, 2017 - Amendment Dear Cedars-Sinai Medical Center:Exclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Reference is made to that certain Exclusive License Agreement regarding the technology titled “Methods of use of compounds that bind to RelA of NFkB” dated October 1, 2017 (as amended from time to time, the “License Agreement”), by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and Kairos Pharma, Ltd, a California corporation (“Licensee”).
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Second Amendment”) is effective this October 11, 2022 (“Second Amendment Effective Date”) by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and ENVIRO THERAPEUTICS INC., a California corporation (“Licensee”).
AGREEMENT OF MERGER BETWEEN KAIROS PHARMA, LTD. AND ACTCELL BIOPHARMA, INC. FILED Secretary of State State of California NOV 13 2019Merger Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
This Agreement of Merger (this “Agreement of Merger”) is entered into as of November 13, 2019, between Kairos Pharma, Ltd., a California corporation (“Surviving Corporation”), and AcTcell Biopharma, Inc., a California corporation (“Merging Corporation”).
Re: Exclusive Option Agreement - Amendment (Sensitization of Tumors to Therapies Through Endoglin Antagonism)Exclusive Option Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Upon execution by you, this letter will serve as the Amendment (“Amendment”) to the Exclusive Option Agreement entered on March 16, 2020 (“Agreement”), by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”), and Enviro Therapeutics, Inc. (“Licensee”) for the above-referenced technology.
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Share Exchange Agreement, dated as of June 3, 2021, (this “Agreement”) is made by and among, Kairos Pharma, Ltd., a California corporation (the “Company” or “Kairos”), on the one hand, and Enviro Therapeutics, Inc., California corporation (“Enviro”) and the shareholders of Enviro set forth on Schedule I hereto (the “Enviro Shareholders”), on the other hand. For purposes of this Agreement, the Company, Enviro and the Enviro Shareholders are sometimes collectively referred to as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is entered into as of this 1st day of October 2017 (“Effective Date”) by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, and Kairos Pharma Ltd. f/k/a NanoGB13, Inc., a California corporation (“Licensee”), with offices at 565 Esplanade, Suite 206, Redondo Beach, CA 90277.
Re: Exclusive License Agreement dated March 12, 2019 – AmendmentExclusive License Agreement • September 29th, 2023 • Kairos Pharma, LTD. • Pharmaceutical preparations
Reference is made to that certain Exclusive License Agreement for the technology titled “Composition and Methods for Treating Cancer and Autoimmune Diseases” dated March 12, 2019 (as amended from time to time, the “License Agreement”), by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation (“CSMC”), and Kairos Pharma, Ltd, a California corporation (“Licensee”).
